Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins.
about
Pharmacokinetic characteristics of therapeutic antibodies.SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB.Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patientsPhysiochemical and biochemical factors influencing the pharmacokinetics of antibody therapeuticsSystemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMDBelatacept: a new biologic and its role in kidney transplantation.Developing the next generation of monoclonal antibodies for the treatment of rheumatoid arthritis.Functional antibody CDR3 fusion proteins with enhanced pharmacological properties.Challenges in monoclonal antibody-based therapies.Genotypes Affecting the Pharmacokinetics of Anticancer Drugs.The use of single chain Fv as targeting agents for immunoliposomes: an update on immunoliposomal drugs for cancer treatment.Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.ADME of monoclonal antibody biotherapeutics: knowledge gaps and emerging tools.Monoclonal antibodies: pharmacokinetics as a basis for new dosage regimens?Biologic concentration testing in inflammatory bowel disease.Dashboard systems: Pharmacokinetic/pharmacodynamic mediated dose optimization for monoclonal antibodies.Clinical Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies Approved to Treat Rheumatoid Arthritis.Therapeutic Monoclonal Antibodies: What Headache Specialists Need to Know.Clinical Decision Support Tools: The Evolution of a Revolution.Pharmacokinetics of Bevacizumab in Three Patients Under the Age of 3 Years with CNS Malignancies.Calibrated flux measurements reveal a nanostructure-stimulated transcytotic pathway.Properties of a general PK/PD model of antibody-ligand interactions for therapeutic antibodies that bind to soluble endogenous targets.Target-directed development and preclinical characterization of the proposed biosimilar rituximab GP2013.Personalized medicine in oncology: where have we come from and where are we going?Changes in systemic vascular endothelial growth factor levels after intravitreal injection of aflibercept in infants with retinopathy of prematurity.Clinical Pharmacokinetics and Pharmacodynamics of Infliximab in the Treatment of Inflammatory Bowel Disease.[Analysis of cardiovascular diseases after the upload phase with intravitreal ranibizumab and bevacizumab in patients with exudative age-related macular degeneration].The FCGR3A polymorphism predicts the response to rituximab-based therapy in patients with non-Hodgkin lymphoma: a meta-analysis.Subfoveal choroidal thickness changes after intravitreal bevacizumab injection for neovascular age-related macular degeneration and diabetic macular edema.Label-Free Quantification of Anti-TNF-α in Patients Treated with Adalimumab Using an Optical Biosensor.
P2860
Q30316517-709EF23E-03C3-4C3E-B29D-E20E33F0BA70Q30490738-64F57509-CBE9-4EAF-BE7E-F586F2B86A4EQ33885497-DB7CD8D0-44CC-49EC-98E4-E4EC3E123C8FQ34275537-A5BAC290-3007-4E25-9430-83A9F5E4E996Q34608306-E792B1F9-3689-4813-B7D2-6D9BD5B26933Q34634807-89A59172-7068-4E8D-AE85-34E937624E5AQ34672043-7B4999D2-5981-416D-B253-53F56DA48CACQ37197904-E5B1178E-FE40-4466-BDEF-E21DAE277185Q37398725-FE933B34-2F9C-4BB9-BAF4-0351F87A64B9Q37685527-37B0B7E0-1AAA-4ED5-AF11-418BA67D1A0AQ37717652-0C235F0F-254C-4EDF-9123-C79D8D87F4CAQ38072598-993E1667-6ECD-4662-B20C-88DAE54671CAQ38128342-0DBFA0E7-FA62-4B61-B5FC-A3FD98CC6648Q38218013-25EEB35B-760C-40AA-95CA-5753B815967CQ38319306-6DF90CDF-DC24-42FC-9C6F-D0715528DE08Q38364464-5E173273-656A-4138-835D-ACEFB147DFF6Q38540353-63188C08-B7BC-4AF8-ACEF-83AE4EF4C49AQ38575679-E6DC3966-C19B-4B0C-8A3E-C6E50CC6F769Q38702792-96344361-EABF-46CA-AF2B-CAF77CD18B0EQ38747217-58D88909-9399-4CA9-9C6F-2BCA786347A9Q38846512-7770E3B1-A1D5-48DD-AD37-467CAE93851BQ41807110-D4045970-E588-4C10-B46E-BD76A23ADF78Q42792700-F0FE231B-0A9D-455F-9166-16195C50FBC7Q44217256-00CE250F-3EE9-407C-95EB-6EFC3686219FQ47229423-DAC01070-D8FA-4527-B76D-8375E526E6D0Q48250204-A96F6C64-28E7-4463-AB06-AA651516B0E7Q48747309-D9680CA0-C238-4251-896B-C95EE18956B0Q51632815-A757DC47-51A9-4522-877C-5EFA9BA44DF2Q53611312-24041ECC-0A19-49BA-9D32-6E3CCFC18C5AQ55259703-40F9F705-2A8D-4E4F-B7B5-5AB68DEB7263
P2860
Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Pharmacokinetics and concentra ...... ntibodies and fusion proteins.
@ast
Pharmacokinetics and concentra ...... ntibodies and fusion proteins.
@en
type
label
Pharmacokinetics and concentra ...... ntibodies and fusion proteins.
@ast
Pharmacokinetics and concentra ...... ntibodies and fusion proteins.
@en
prefLabel
Pharmacokinetics and concentra ...... ntibodies and fusion proteins.
@ast
Pharmacokinetics and concentra ...... ntibodies and fusion proteins.
@en
P2860
P356
P1476
Pharmacokinetics and concentra ...... ntibodies and fusion proteins.
@en
P2093
David Ternant
Gilles Paintaud
P2860
P304
P356
10.1517/14712598.5.1.S37
P407
P478
P577
2005-09-01T00:00:00Z